Market Overview

The Australia diabetes products market represents a critical healthcare segment experiencing substantial growth driven by increasing diabetes prevalence and advancing medical technologies. Market dynamics indicate robust expansion as the country faces rising Type 1 and Type 2 diabetes cases, with approximately 6.1% of the Australian population currently diagnosed with diabetes. The market encompasses comprehensive diabetes management solutions including blood glucose monitoring devices, insulin delivery systems, continuous glucose monitors, and diabetic care accessories.

Healthcare infrastructure in Australia supports widespread adoption of innovative diabetes management technologies, with the National Diabetes Services Scheme facilitating access to essential diabetes products. The market demonstrates strong growth potential, projected to expand at a significant CAGR of 7.2% through the forecast period. Technological advancement remains a key driver, with smart glucose monitoring systems and connected insulin delivery devices gaining substantial market traction among Australian healthcare providers and patients.

Regional distribution shows concentrated market activity in major metropolitan areas including Sydney, Melbourne, and Brisbane, while rural and remote areas present emerging opportunities for telemedicine-integrated diabetes management solutions. The market benefits from supportive government initiatives and increasing healthcare expenditure focused on chronic disease management and prevention strategies.

Meaning

The Australia diabetes products market refers to the comprehensive ecosystem of medical devices, technologies, and consumables designed for diabetes diagnosis, monitoring, treatment, and management within the Australian healthcare system. This market encompasses blood glucose meters, test strips, lancets, insulin delivery systems, continuous glucose monitoring devices, insulin pumps, and associated digital health solutions specifically tailored for Australian regulatory requirements and healthcare practices.

Market scope includes both prescription and over-the-counter diabetes management products distributed through hospitals, clinics, pharmacies, and direct-to-consumer channels. The definition extends to encompass emerging technologies such as artificial pancreas systems, smart insulin pens, and mobile health applications that integrate with traditional diabetes management devices to provide comprehensive care solutions.

Healthcare integration within this market involves coordination between medical device manufacturers, pharmaceutical companies, healthcare providers, and government health agencies to ensure accessible, effective diabetes care across diverse Australian populations and geographic regions.

Executive Summary

Market performance in Australia’s diabetes products sector demonstrates exceptional growth momentum, driven by increasing diabetes prevalence and technological innovation in glucose monitoring and insulin delivery systems. The market benefits from strong government support through the National Diabetes Services Scheme and Medicare coverage for essential diabetes management products, creating favorable conditions for sustained expansion.

Key growth drivers include rising obesity rates contributing to Type 2 diabetes incidence, an aging population with increased diabetes risk, and growing awareness of diabetes complications driving demand for advanced monitoring solutions. Approximately 85% of diabetes cases in Australia are Type 2, creating substantial market opportunities for lifestyle management and monitoring technologies.

Technological advancement represents a primary market catalyst, with continuous glucose monitoring adoption increasing by 42% annually among Australian diabetes patients. Smart insulin delivery systems and integrated digital health platforms are transforming traditional diabetes management approaches, offering improved patient outcomes and enhanced quality of life.

Competitive landscape features established global manufacturers alongside emerging Australian healthcare technology companies, creating a dynamic market environment focused on innovation and patient-centric solutions. Market consolidation trends and strategic partnerships are shaping the industry structure while maintaining competitive pricing and product accessibility.

Key Market Insights

Market segmentation reveals distinct growth patterns across product categories, with continuous glucose monitoring systems experiencing the highest adoption rates among Australian diabetes patients. The following insights highlight critical market developments:

1. Blood Glucose Monitoring: Traditional glucose meters maintain significant market share while smart-connected devices gain 28% market penetration annually
2. Insulin Delivery Systems: Insulin pump adoption increases steadily, particularly among Type 1 diabetes patients seeking improved glycemic control
3. Continuous Glucose Monitoring: Rapid technology adoption driven by Medicare coverage expansion and clinical evidence supporting improved outcomes
4. Digital Health Integration: Mobile applications and telemedicine platforms enhance traditional diabetes management approaches
5. Consumables Market: Test strips and lancets represent stable revenue streams with consistent demand patterns
6. Pediatric Diabetes Products: Specialized solutions for children and adolescents show strong growth potential
7. Rural Healthcare Solutions: Remote monitoring technologies address geographic healthcare access challenges
8. Preventive Care Products: Pre-diabetes screening and monitoring devices gain market traction

Consumer preferences increasingly favor integrated diabetes management ecosystems that combine multiple monitoring and treatment modalities within unified platforms, reflecting broader healthcare digitization trends across Australia.

Market Drivers

Diabetes prevalence continues rising across Australia, creating fundamental demand for comprehensive diabetes management products and services. The primary drivers propelling market growth include demographic, technological, and healthcare policy factors that collectively support sustained market expansion.

Aging population dynamics significantly impact market growth, with Australians aged 65 and older representing the fastest-growing demographic segment at highest risk for Type 2 diabetes development. This demographic shift creates sustained demand for user-friendly diabetes management technologies designed for older adults with varying technological comfort levels.

Obesity epidemic contributes substantially to Type 2 diabetes incidence, with approximately 67% of Australian adults classified as overweight or obese. This health crisis drives demand for comprehensive diabetes prevention and management solutions, including lifestyle monitoring devices and integrated health management platforms.

Government healthcare initiatives provide strong market support through the National Diabetes Services Scheme, Medicare coverage expansion, and chronic disease management programs. These policies improve product accessibility and affordability, driving broader market adoption across diverse socioeconomic groups.

Technological innovation accelerates market growth through development of more accurate, convenient, and connected diabetes management devices. Smart glucose monitoring systems, artificial intelligence-powered insulin delivery, and integrated mobile health platforms enhance patient engagement and clinical outcomes.

Healthcare digitization trends support adoption of connected diabetes management solutions that integrate with electronic health records and telemedicine platforms, improving care coordination and patient monitoring capabilities across Australia’s healthcare system.

Market Restraints

Cost considerations present significant barriers to market growth, particularly for advanced diabetes management technologies not fully covered by government healthcare programs. High out-of-pocket expenses for premium glucose monitoring systems and insulin pumps limit accessibility for many Australian patients, constraining market expansion potential.

Regulatory complexity creates challenges for new product introductions and market entry, with Therapeutic Goods Administration approval processes requiring substantial time and financial investment. These regulatory requirements can delay innovative product launches and increase development costs for manufacturers.

Healthcare workforce limitations impact market growth through insufficient diabetes educator availability and limited specialist access, particularly in rural and remote areas. This constraint affects patient education, device training, and ongoing support services essential for successful diabetes management product adoption.

Technology adoption barriers among older adults and technologically inexperienced patients limit uptake of advanced diabetes management systems. Digital literacy gaps and resistance to complex medical devices constrain market penetration for sophisticated monitoring and treatment technologies.

Insurance coverage gaps for certain diabetes products and services create financial barriers that prevent optimal diabetes management for some patient populations. Limited coverage for continuous glucose monitoring and insulin pump supplies affects market accessibility and growth potential.

Geographic healthcare disparities between urban and rural areas create uneven market development, with remote regions experiencing limited access to specialized diabetes products and support services, constraining overall market growth and patient outcomes.

Market Opportunities

Emerging technologies present substantial growth opportunities within Australia’s diabetes products market, particularly in areas of artificial intelligence, machine learning, and predictive analytics for glucose management. These innovations offer potential for developing next-generation diabetes management solutions that provide personalized treatment recommendations and automated insulin delivery systems.

Rural healthcare expansion represents a significant untapped market opportunity, with telemedicine-integrated diabetes management solutions addressing geographic access barriers. Remote monitoring technologies and mobile health platforms can extend specialized diabetes care to underserved regional and rural communities across Australia.

Preventive care market offers substantial growth potential through development of pre-diabetes screening and early intervention products. As healthcare systems increasingly focus on prevention rather than treatment, demand for risk assessment tools and lifestyle management technologies continues expanding.

Pediatric diabetes solutions present specialized market opportunities, with growing recognition of unique needs for children and adolescents with diabetes. Age-appropriate monitoring devices, educational tools, and family-centered care platforms represent emerging market segments with strong growth potential.

Digital health integration creates opportunities for comprehensive diabetes management ecosystems that combine traditional medical devices with mobile applications, cloud-based data analytics, and artificial intelligence-powered insights. These integrated solutions offer enhanced patient engagement and improved clinical outcomes.

Workplace wellness programs represent emerging opportunities for diabetes prevention and management products within corporate health initiatives. Employee health screening, lifestyle management tools, and workplace-based diabetes education programs create new market channels and revenue streams.

Market Dynamics

Supply chain evolution within Australia’s diabetes products market reflects broader healthcare industry transformation, with manufacturers adapting distribution strategies to accommodate changing consumer preferences and healthcare delivery models. Direct-to-consumer channels gain prominence alongside traditional pharmacy and hospital distribution networks.

Competitive intensity increases as established medical device companies face competition from innovative healthcare technology startups and digital health platforms. This dynamic environment drives continuous product innovation and competitive pricing strategies while maintaining focus on patient outcomes and clinical effectiveness.

Regulatory landscape continues evolving to accommodate emerging diabetes management technologies, with the Therapeutic Goods Administration adapting approval processes for digital health solutions and connected medical devices. These regulatory developments influence market entry strategies and product development timelines.

Healthcare reimbursement policies significantly impact market dynamics, with Medicare coverage decisions and private insurance policies affecting product accessibility and adoption rates. Recent expansions in continuous glucose monitoring coverage demonstrate positive policy trends supporting market growth.

Patient empowerment trends drive demand for self-monitoring and self-management diabetes products that enable greater patient autonomy and engagement in their healthcare. This shift toward patient-centric care models influences product design and marketing strategies across the industry.

Data privacy concerns and cybersecurity requirements increasingly influence product development and market acceptance, with manufacturers investing in robust security measures for connected diabetes management devices and digital health platforms.

Research Methodology

Comprehensive market analysis employs multi-faceted research approaches combining primary and secondary data sources to provide accurate insights into Australia’s diabetes products market. The methodology encompasses quantitative and qualitative research techniques designed to capture market dynamics, competitive landscape, and future growth projections.

Primary research involves extensive interviews with healthcare professionals, diabetes educators, patients, and industry stakeholders across Australia’s major metropolitan and regional areas. Survey methodologies capture patient preferences, product usage patterns, and satisfaction levels with current diabetes management solutions.

Secondary research incorporates analysis of government health statistics, medical literature, industry reports, and regulatory filings to establish comprehensive market context. Data sources include the Australian Institute of Health and Welfare, Diabetes Australia, and various medical research institutions.

Market sizing methodology utilizes bottom-up and top-down approaches to validate market estimates and growth projections. Analysis considers patient population demographics, product adoption rates, pricing trends, and healthcare expenditure patterns specific to diabetes management.

Competitive intelligence gathering involves monitoring company financial reports, product launches, regulatory approvals, and strategic partnerships within the Australian diabetes products market. This analysis provides insights into market share dynamics and competitive positioning strategies.

Trend analysis incorporates examination of technological developments, regulatory changes, and healthcare policy evolution to identify emerging market opportunities and potential disruptions affecting the diabetes products industry in Australia.

Regional Analysis

New South Wales dominates the Australian diabetes products market, accounting for approximately 32% of national market share due to its large population base and concentrated healthcare infrastructure in Sydney and surrounding metropolitan areas. The state benefits from strong research institutions and medical device companies driving innovation in diabetes management technologies.

Victoria represents the second-largest regional market with 25% market share, supported by Melbourne’s robust healthcare system and significant diabetes patient population. The state demonstrates strong adoption rates for advanced glucose monitoring technologies and insulin delivery systems among both urban and regional communities.

Queensland shows rapid market growth with 20% market share, driven by population growth and increasing diabetes prevalence in both metropolitan Brisbane and regional areas. The state’s diverse geography creates opportunities for telemedicine-integrated diabetes management solutions serving remote communities.

Western Australia maintains 12% market share with concentrated activity in Perth and growing demand for diabetes products in mining communities and regional centers. The state’s geographic challenges drive innovation in remote patient monitoring and mobile health solutions.

South Australia accounts for 7% market share with Adelaide serving as a regional hub for diabetes care and medical device distribution. The state demonstrates strong government support for diabetes prevention and management programs.

Tasmania, Northern Territory, and Australian Capital Territory collectively represent 4% market share but show potential for growth through targeted diabetes management programs and improved healthcare access initiatives.

Competitive Landscape

Market leadership in Australia’s diabetes products sector features a combination of established global medical device manufacturers and emerging local healthcare technology companies. The competitive environment emphasizes innovation, patient outcomes, and healthcare system integration.

1. Abbott Laboratories – Leading provider of continuous glucose monitoring systems with strong market presence through FreeStyle Libre technology
2. Roche Diabetes Care – Established manufacturer of blood glucose monitoring systems and diabetes management solutions
3. Medtronic – Market leader in insulin pump technology and integrated diabetes management systems
4. Dexcom – Innovative continuous glucose monitoring specialist with growing Australian market share
5. Johnson & Johnson – Comprehensive diabetes care portfolio including monitoring devices and digital health solutions
6. Ascensia Diabetes Care – Blood glucose monitoring systems and diabetes management technologies
7. Insulet Corporation – Tubeless insulin pump systems and automated insulin delivery solutions
8. Tandem Diabetes Care – Advanced insulin pump technology with smartphone integration capabilities

Strategic partnerships between global manufacturers and Australian healthcare providers create competitive advantages through improved product distribution, clinical support, and patient education programs. These collaborations enhance market penetration and customer loyalty.

Innovation focus drives competitive differentiation through development of user-friendly interfaces, improved accuracy, and integration with digital health platforms. Companies invest heavily in research and development to maintain technological leadership and market position.

Segmentation

Product segmentation within Australia’s diabetes products market reveals distinct categories with varying growth rates and market dynamics. Each segment addresses specific patient needs and clinical requirements across the diabetes management spectrum.

By Product Type:

• Blood Glucose Monitoring Devices: Traditional and smart glucose meters with connectivity features
• Continuous Glucose Monitoring Systems: Real-time glucose tracking with smartphone integration
• Insulin Delivery Systems: Insulin pens, pumps, and automated delivery devices
• Diabetes Testing Supplies: Test strips, lancets, and control solutions
• Digital Health Solutions: Mobile applications and telemedicine platforms

By Diabetes Type:

• Type 1 Diabetes Products: Specialized solutions for insulin-dependent patients
• Type 2 Diabetes Products: Comprehensive management tools for lifestyle and medication management
• Gestational Diabetes Products: Monitoring solutions for pregnancy-related diabetes

By End User:

• Hospitals and Clinics: Professional-grade monitoring and treatment systems
• Home Healthcare: Patient-friendly devices for self-monitoring and management
• Diagnostic Centers: Specialized testing equipment and laboratory solutions

By Distribution Channel:

• Pharmacy Retail: Traditional and online pharmacy distribution
• Hospital Pharmacies: Institutional procurement and distribution
• Direct-to-Consumer: Manufacturer direct sales and subscription services

Category-wise Insights

Blood glucose monitoring devices maintain the largest market segment, with traditional glucose meters evolving toward smart-connected systems offering data sharing and trend analysis capabilities. Market penetration of connected devices reaches 35% adoption rate among Australian diabetes patients, driven by improved convenience and clinical insights.

Continuous glucose monitoring systems represent the fastest-growing segment, experiencing rapid adoption due to Medicare coverage expansion and clinical evidence supporting improved glycemic control. These systems offer real-time glucose data and trend alerts, significantly enhancing diabetes management effectiveness.

Insulin delivery systems show steady growth with increasing preference for insulin pumps and smart insulin pens among Type 1 diabetes patients. Advanced features including automated insulin delivery and smartphone connectivity drive market expansion and patient satisfaction.

Testing supplies provide stable revenue streams with consistent demand for test strips, lancets, and control solutions. This segment benefits from regular consumable replacement cycles and expanding glucose monitoring frequency among diabetes patients.

Digital health solutions emerge as a high-growth category, with mobile applications and telemedicine platforms gaining 48% user adoption among tech-savvy diabetes patients. These solutions enhance traditional device functionality through data analytics and remote healthcare connectivity.

Pediatric diabetes products represent a specialized but growing segment, with age-appropriate devices and educational tools designed specifically for children and adolescents with diabetes. This category emphasizes user-friendly interfaces and family-centered care approaches.

Key Benefits for Industry Participants and Stakeholders

Healthcare providers benefit from advanced diabetes management technologies that improve patient outcomes, reduce complications, and enhance care efficiency. Integrated monitoring systems provide comprehensive patient data supporting evidence-based treatment decisions and personalized care plans.

Patients experience improved quality of life through convenient, accurate, and user-friendly diabetes management products. Modern devices offer enhanced comfort, reduced testing frequency, and better glycemic control, leading to decreased diabetes-related complications and healthcare costs.

Manufacturers gain access to a growing market with strong government support and increasing healthcare expenditure focused on chronic disease management. Innovation opportunities in digital health integration and personalized medicine create competitive advantages and revenue growth potential.

Healthcare systems achieve cost savings through improved diabetes management that reduces hospitalizations, emergency department visits, and long-term complications. Preventive care technologies and remote monitoring solutions enhance resource efficiency and patient access to specialized care.

Government agencies benefit from reduced healthcare burden and improved population health outcomes through effective diabetes prevention and management programs. Investment in diabetes products and technologies supports broader public health objectives and healthcare sustainability.

Insurance providers experience reduced claims costs through improved diabetes management that prevents expensive complications and hospitalizations. Coverage of preventive diabetes technologies demonstrates positive return on investment through long-term healthcare cost reduction.

SWOT Analysis

Strengths:

• Strong Healthcare Infrastructure: Australia’s robust healthcare system supports widespread adoption of advanced diabetes technologies
• Government Support: National Diabetes Services Scheme and Medicare coverage facilitate product accessibility
• High Healthcare Awareness: Educated population with strong health consciousness drives demand for quality diabetes products
• Regulatory Framework: Well-established TGA approval processes ensure product safety and efficacy

Weaknesses:

• Geographic Challenges: Vast distances and sparse population in rural areas limit healthcare access
• Cost Barriers: High prices for advanced diabetes technologies create accessibility limitations
• Technology Adoption Gaps: Varying digital literacy levels affect smart device uptake
• Specialist Shortages: Limited diabetes educators and specialists in regional areas

Opportunities:

• Telemedicine Expansion: Remote healthcare delivery creates opportunities for digital diabetes solutions
• Preventive Care Focus: Increasing emphasis on prevention drives demand for early detection technologies
• Aging Population: Demographic trends create sustained demand for diabetes management products
• Technology Integration: AI and machine learning applications offer personalized treatment solutions

Threats:

• Regulatory Changes: Evolving approval requirements may impact product development timelines
• Economic Pressures: Healthcare budget constraints could affect reimbursement policies
• Cybersecurity Risks: Connected devices face increasing data security challenges
• Competition Intensity: Market saturation in some segments creates pricing pressures

Market Key Trends

Digital health integration represents the most significant trend transforming Australia’s diabetes products market, with manufacturers developing comprehensive ecosystems that combine traditional medical devices with mobile applications, cloud analytics, and artificial intelligence capabilities. This integration enhances patient engagement and clinical decision-making.

Personalized medicine approaches gain momentum through development of diabetes management solutions tailored to individual patient characteristics, lifestyle factors, and treatment responses. Advanced algorithms analyze patient data to provide customized recommendations for glucose management and insulin dosing.

Continuous monitoring adoption accelerates across all diabetes types, with patients and healthcare providers recognizing the clinical benefits of real-time glucose data. This trend drives innovation in sensor technology, accuracy improvements, and user interface design.

Automated insulin delivery systems emerge as game-changing technology, combining continuous glucose monitoring with intelligent insulin pumps to create artificial pancreas solutions. These systems reduce patient burden while improving glycemic control and quality of life.

Telemedicine integration becomes essential for diabetes care delivery, particularly in rural and remote areas. Remote monitoring capabilities and virtual consultations expand access to specialized diabetes care across Australia’s diverse geographic landscape.

Preventive care emphasis shifts market focus toward early detection and intervention technologies that identify pre-diabetes and diabetes risk factors. This trend creates opportunities for screening devices and lifestyle management tools.

Sustainability initiatives influence product development and packaging design, with manufacturers adopting environmentally responsible practices in response to growing consumer and regulatory expectations for sustainable healthcare solutions.

Key Industry Developments

Regulatory approvals for next-generation diabetes management technologies continue expanding market opportunities, with the Therapeutic Goods Administration approving innovative continuous glucose monitoring systems and automated insulin delivery devices for Australian patients.

Medicare coverage expansion for continuous glucose monitoring represents a significant industry development, improving accessibility for Type 1 and Type 2 diabetes patients while driving market growth and adoption rates across diverse patient populations.

Strategic partnerships between global medical device manufacturers and Australian healthcare providers create integrated care delivery models that combine advanced diabetes technologies with comprehensive patient support services and clinical expertise.

Research collaborations between universities, medical research institutions, and industry partners accelerate innovation in diabetes management technologies, with several Australian-based research projects contributing to global diabetes care advancement.

Digital health platform launches by major manufacturers introduce comprehensive diabetes management ecosystems that integrate multiple devices, data analytics, and healthcare provider connectivity within unified patient-centric platforms.

Acquisition activities within the industry consolidate market leadership while expanding product portfolios and distribution capabilities. These transactions enhance competitive positioning and accelerate technology development timelines.

Clinical evidence generation through real-world studies and clinical trials demonstrates improved patient outcomes with advanced diabetes management technologies, supporting reimbursement decisions and clinical adoption recommendations.

Analyst Suggestions

Market participants should prioritize development of integrated diabetes management platforms that combine multiple monitoring and treatment modalities within unified, user-friendly systems. MarkWide Research analysis indicates that comprehensive solutions addressing multiple patient needs demonstrate superior market acceptance and customer loyalty.

Investment focus should emphasize digital health capabilities and artificial intelligence integration to differentiate products in an increasingly competitive market. Companies developing predictive analytics and personalized treatment recommendations position themselves for long-term success in the evolving healthcare landscape.

Geographic expansion strategies should prioritize rural and remote market penetration through telemedicine-enabled solutions and mobile health platforms. These underserved markets represent significant growth opportunities while addressing critical healthcare access challenges.

Partnership development with Australian healthcare providers, diabetes educators, and government agencies creates competitive advantages through improved market access, clinical validation, and patient support services. Collaborative approaches enhance product adoption and market penetration.

Regulatory strategy should anticipate evolving TGA requirements for digital health solutions and connected medical devices. Proactive engagement with regulatory processes ensures timely market entry and compliance with emerging cybersecurity and data privacy standards.

Patient education initiatives represent critical success factors for advanced diabetes management technologies. Companies investing in comprehensive training programs and ongoing support services achieve higher adoption rates and customer satisfaction levels.

Future Outlook

Market growth trajectory remains strongly positive for Australia’s diabetes products market, with sustained expansion expected through increasing diabetes prevalence, technological advancement, and supportive healthcare policies. The market demonstrates resilience and adaptability to changing healthcare delivery models and patient preferences.

Technology evolution will continue driving market transformation through artificial intelligence integration, improved sensor accuracy, and enhanced connectivity features. Next-generation diabetes management systems will offer unprecedented levels of automation and personalization, revolutionizing patient care approaches.

Healthcare integration trends support development of comprehensive diabetes care ecosystems that connect patients, healthcare providers, and technology platforms within seamless care delivery models. This integration enhances clinical outcomes while improving healthcare efficiency and cost-effectiveness.

Regulatory landscape evolution will accommodate emerging technologies while maintaining safety and efficacy standards. Adaptive regulatory frameworks will support innovation while ensuring patient protection and data security in an increasingly connected healthcare environment.

Market consolidation activities may reshape competitive dynamics through strategic acquisitions and partnerships, creating larger, more comprehensive diabetes care companies with enhanced capabilities and market reach. This consolidation will drive innovation while maintaining competitive pricing.

Patient empowerment trends will continue influencing product development toward user-friendly, autonomous diabetes management solutions that reduce healthcare provider dependence while maintaining clinical effectiveness. This shift supports broader healthcare sustainability objectives and patient satisfaction goals.

Conclusion

Australia’s diabetes products market presents exceptional growth opportunities driven by increasing diabetes prevalence, technological innovation, and supportive healthcare infrastructure. The market demonstrates strong fundamentals with government backing through the National Diabetes Services Scheme and expanding Medicare coverage for advanced diabetes management technologies.

Competitive dynamics favor companies developing integrated, patient-centric solutions that combine traditional medical devices with digital health capabilities and artificial intelligence. Market success requires focus on clinical outcomes, user experience, and comprehensive patient support services that address diverse needs across Australia’s geographic and demographic landscape.

Future market development will be shaped by continued technological advancement, regulatory evolution, and changing healthcare delivery models that emphasize prevention, personalization, and patient empowerment. Companies positioning themselves at the intersection of medical device innovation and digital health transformation will capture the greatest market opportunities while contributing to improved diabetes care outcomes across Australia.